www.wjpr.net │ Vol 11, Issue 2, 2022. │ ISO 9001:2015 Certified Journal │ Chaudhary. World Journal of Pharmaceutical Research 1409 EVALUATION OF AMELIORATIVE EFFECT OF QUERCETIN AND CANDESARTAN IN ISOPRENALINE INDUCED MYOCARDIAL INFARCTION Sarika Chaudhary* Department of Pharmacology, I. T. S College of Pharmacy, Muradnagar, Ghaziabad, India. ABSTRACT Background: Isoprenaline (IP), a synthetic catecholamine and β- adrenergic agonist increases heart rate and exhaust energy reservoir of cardiac myocytes leading to cell death. It induces myocardial necrosis via multiple modes of action in experimental animals. Oxidative stress is more probably one the main mechanisms through which catecholamines exert their toxic effects. Objective: The objective of the study was to evaluate the protective effects of angiotensin II type -1 receptor antagonist (candesartan) along with quercetin in isoproterenol - induced myocardial infarction rat model. Method: Rats were treated with isoproterenol (85 mg/kg, subcutaneously injected, once at an interval of 24 h for 2 consecutive days), to induce myocardial infarction. Individual and combined treatment of candesartan (5 mg/kg/day, p.o.) and quercetin (10 mg/kg/day, p.o.) was administered for four weeks. Result: Following cardiomyopathy, heart/body weight ratio, serum creatine kinase (CK-MB), lactate dehydrogenase (LDH) levels were elevated in addition to altered lipid profile. The combination therapy of candesartan and quercetin significantly restored the values to normal. The increased level of lipid peroxides (MDA), serum troponin-T (cTnT) and nitric oxide (NO) level along with attenuating cardiac antioxidant profile i.e. superoxide dismutase (SOD) and catalase (CAT) and GSH activities were reversed. Morphometry and histopathologic changes represented beneficial effect of single and combination administration of treatment drugs. Findings suggest that pre-treatment with candesartan, quercetin or both significantly decreases adriamycin induced cardiac toxicity. Conclusion: The ameliorative effects obtained by candesartan were potentially augmented and more notable when combined with World Journal of Pharmaceutical Research SJIF Impact Factor 8.084 Volume 11, Issue 2, 1409-1422. Research Article ISSN 2277– 7105 *Corresponding Author Sarika Chaudhary Department of Pharmacology, I. T. S College of Pharmacy, Muradnagar, Ghaziabad, India. Article Received on 25 Nov. 2021, Revised on 15 Dec. 2021, Accepted on 05 January 2022 DOI: 10.20959/wjpr20222-22861